Bradbury Daniel's Form 4 filing
Castle Biosciences Inc (CSTL) · filed Jan 8, 2025
- Accession no.
- 0001447362-25-000008
- Filed
- Jan 8, 2025
- Trade date
- Jan 6, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 9 non-derivative transactions. Open-market sales total $229.2K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bradbury DanielCIK 0001236397 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 6, 2025 | Common Stock | SSaleDisposed | −1,530 | $28.39F2 | −$43,436.7 | 8,504 | Indirect | |
| Jan 6, 2025 | Common Stock | SSaleDisposed | −434 | $28.39F2 | −$12,321.26 | 2,416 | Indirect | |
| Jan 6, 2025 | Common Stock | SSaleDisposed | −434 | $28.39F2 | −$12,321.26 | 2,416 | Indirect | |
| Jan 6, 2025 | Common Stock | SSaleDisposed | −3,015 | $29.41F6 | −$88,671.15 | 5,489 | Indirect | |
| Jan 6, 2025 | Common Stock | SSaleDisposed | −857 | $29.41F6 | −$25,204.37 | 1,559 | Indirect | |
| Jan 6, 2025 | Common Stock | SSaleDisposed | −857 | $29.41F6 | −$25,204.37 | 1,559 | Indirect | |
| Jan 6, 2025 | Common Stock | SSaleDisposed | −472 | $29.82F7 | −$14,075.04 | 5,017 | Indirect | |
| Jan 6, 2025 | Common Stock | SSaleDisposed | −134 | $29.82F7 | −$3,995.88 | 1,425 | Indirect | |
| Jan 6, 2025 | Common Stock | SSaleDisposed | −134 | $29.82F7 | −$3,995.88 | 1,425 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $27.78 to $28.73, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 3 transactions in Table I.
- F6
This transaction was executed in multiple trades at prices ranging from $28.84 to $29.77, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 3 transactions in Table I.
- F7
This transaction was executed in multiple trades at prices ranging from $29.78 to $29.87, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 3 transactions in Table I.